Atea Pharmaceuticals Meets Both Its Primary and Secondary Endpoints in the Phase 3 C-BEYOND North America Trial Evaluating Bemnifosbuvir/Ruzasvir for Hepatitis C Virus
Globe Newswire•28/07/2026•07:00 ET
0
Whiz Insights
Get started
Create a free account to read the full story.